Video above: FDA votes to authorize more COVID-19 boosters, mix-and-matching doses in some casesA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — ...

A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...

The U.S. Food and Drug Administration has authorized booster shots of the Moderna and Pfizer COVID-19 vaccines for all adults ages 18 and older. On Friday, the FDA announced it had amended the ...

WASHINGTON -- The Biden administration purchased an additional 200 million doses of Pfizer-BioNTech's COVID-19 vaccine to prepare for potential additional vaccine needs in the US, an administration ...

The Food and Drug Administration today authorized both Pfizer and Moderna to give a second booster dose of their COVID-19 vaccines to individuals aged 50 and older and to those who are ...

To help fend off another wave of Covid-19, people will need a fourth dose of vaccine, Pfizer CEO Albert Bourla said Sunday. "Many variants are coming, and Omicron was the first one that was able to ...

Now that the federal government is recommending that many COVID-vaccinated Americans receive booster shots starting this fall, it’s important to know what a “booster” is and how it differs from a ...

Moderna booster shots, Pfizer booster shots and Johnson & Johnson booster shots of the COVID-19 vaccine are now available, following a thorough in-depth review process from the Food and Drug ...

Pfizer and BioNTech said Wednesday that initial lab tests show that the omicron variant partly escapes protection offered by the companies' two-dose regimen of their COVID-19 vaccine. However, those ...

Moderna announced on Wednesday it has completed its submission to the US Food and Drug Administration for full approval of its COVID-19 vaccine for people age 18 and older, and Pfizer and BioNTech ...

Pfizer on Monday announced it submitted data to the Food and Drug Administration regarding the results of Phase 1 trials for a potential COVID-19 vaccine booster shot. In a press release, Pfizer said ...